The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy
LCIPS is an independent predictor of pCR in patients with NSCLC receiving neoadjuvant immunochemotherapy and is associated with improved DFS and survival outcomes. This novel index offers valuable guidance for personalized treatment strategies.
Authors
- Tong Chen (ORCID: https://orcid.org/0000-0003-3805-4138)
- Fang Liu (ORCID: https://orcid.org/0000-0001-5248-9141)
- Yuyan Xie (ORCID: https://orcid.org/0009-0009-5640-6177)
- Xiaosong Xiang (ORCID: https://orcid.org/0000-0001-9587-8219)
- Menglin Fan
- Hongyan Li (ORCID: https://orcid.org/0000-0002-7436-6393)
- Zhihao Shi
Institutions
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1567565
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Beijing Medical and Health Foundation
- Wu Jieping Medical Foundation